Publication of the results of our study on the expectations of a robotic arm and the actual experience of using the innovative robotic aid (digitROBOT) in amyotrophic lateral sclerosis (ALS). The users’ experiences underline the broad spectrum of possible applications for robotic arms in ALS. The positive user experiences and the high level of satisfaction show that robotic arms are a valuable treatment option for ALS patients with severe motor deficits in the arms.

This study shows the association of ALS phenotypes with the concentration of neurofilament light chain (NfL) in blood serum, disease progression and survival. ALS phenotypes have a significant influence on the concentration of NfL in blood serum and should be considered as an independent factor for NfL analyses in studies and clinical practice.

In a study with 14 ALS outpatient clinics, the significance of the serum neurofilament light chain (sNfL) in ALS was investigated in a broad spectrum of disease courses with regard to the progression and duration of the disease.

Publication on the recording of the ALS Functional Rating Scale (ALSFRS-R) via web portal or ALS app. The study analyzed data from 620 people with ALS who completed the ALS Functional Rating Scale digitally. The results were impressive: people with ALS completed the ALS Functional Rating Scale digitally 9.6 times per year.

Publication of the results of our study on the benefits of therapeutic exercise trainers (digitTHERA) in amyotrophic lateral sclerosis (ALS). Between February 2019 and January 2021, data from 144 people with ALS who use a movement trainer was collected and evaluated at 10 ALS centers in Germany.

The FU Berlin, the WWU Münster and the Einstein Center Digital Future have researched our digital supply and research platform. The results are available in a publication for an international readership.

Scientific study of symptomatic treatment with medication in amyotrophic lateral sclerosis (ALS). Data from 2,392 people with ALS who took part in our digitally supported medication management were analyzed.

In this study of 37 patients with ALS, THC:CBD was used in a wide dose range to treat spasticity. The data suggest that the drug was taken based on the individual needs and preferences of the patients. Overall treatment satisfaction with THC:CBD was high. The results suggest that THC:CBD is a valuable addition to the spectrum of symptomatic therapy for spasticity in people with ALS.

We surveyed 256 people with ALS between 07/2014 and 08/2017 about their treatment. The analysis of the data shows that the satisfaction of ALS patients with physiotherapy, occupational therapy and speech therapy is predominantly high.

The provision of medical aids at 12 leading German ALS centers was evaluated over a period of 4 years. The data of 1,494 ALS patients with 11,364 assistive devices were analyzed via the care platform Ambulanzpartner.

NeuroTransmitter sees itself as a discussion forum and leading professional-political medium for neurologists and psychiatrists in Germany. Our aim is to provide comprehensive information and a sound understanding for outpatient partners in the target group.

A first scientific evaluation of aggregated care data from the Outpatient Partner Network. For the first time, the data from the digitized care processes provide an independent direct comparison of services provided by health insurance companies in the area of assistive devices for people with ALS.

The specialist journal “Klinische Neurophysiologie” is aimed at neurophysiologists, neurologists, neurosurgeons and neurologists in hospitals and practices. In the article, Ambulanzpartner is described in detail using the example of care for people with amyotrophic lateral sclerosis (ALS).